Abstract:
The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor.
Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.
Abstract:
A process for the nitrilation of a fatty acid or of a fatty acid ester, which is optionally unsaturated, by reacting the fatty acid or fatty acid ester with ammonia in a reactor operating continuously in the gas phase or in the mixed gas-liquid phase in a temperature range of from 180 to 400° C., in the presence of a solid catalyst comprising at least one metal oxide, the metal of which belongs to column 8 of the periodic table, as a mixture with at least one metal oxide chosen from aluminum oxides, zirconium oxides, niobium oxides, tantalum oxides and tin oxides, the metal oxide(s), the metal of which belongs to column 8, being present in a volume ratio of 0.1 to 0.6 relative to the volume of the mixture of all the oxides.
Abstract:
The present invention provides an industrially advantageous method for producing an optically active naphthalene compound useful as a therapeutic agent for dermatitis or the like. Specifically, the present invention provides a method for producing an optically active naphthalene compound [I], which comprises: a step of reacting a compound [a-1] and a compound [b-1] with each other in the presence of a base and a catalyst that is composed of a Pd compound and a tertiary phosphine ligand (step a); a step of asymmetrically hydrogenating a compound [c-1] in the presence of a hydrogen donor and a complex that is prepared from a ruthenium compound and a chiral ligand, or alternatively in the presence of an optically active oxazaborolidine compound (a CBS catalyst) and a boron hydride compound (step b); and a step of treating a compound [d-1] with a reducing agent (step c). (In the above formulae, Ra and Rb represent the same or different lower alkyl groups; and X1 represents a halogen atom.).
Abstract:
The present invention generally relates to processes for converting acrylate esters or a derivative thereof to difluoropropionic acid or a derivative thereof. This process is generally performed using fluorine gas in a hydrofluorocarbon solvent.
Abstract:
The invention relates to a method for cleaving unsaturated fatty chains comprising a step of oxidative cleavage in which at least one fatty acid derivative having at least one unsaturation is reacted in the liquid phase with hydrogen peroxide in the presence of a catalyst for activating the reaction of oxidative cleavage and of molecular oxygen and in the absence of organic solvent.
Abstract:
A process is disclosed for producing organic nitriles such as Acetonitrile or Hydrogen Cyanide, in which yields may exceed 90%, undesirable by-products are not produced, and handling of ammonia gas is avoided. In one aspect, a process includes preparing a feed including ammonium salts and water; introducing the feed into a reactor containing a catalyst; and heating the feed in the presence of the catalyst. The catalyst may advantageously include molybdenum on a silica or silica alumina support. The feed may be ammonium acetate in water with about 50 wt % ammonium acetate and the balance water or ammonium formate in water. In another aspect, a process includes preparing a feed including ammonium hydroxide and acetic acid; introducing the feed into a reactor containing a catalyst; and heating the feed in the presence of the catalyst.
Abstract:
The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.
Abstract:
The invention relates to novel cyclic hydrocarbon compounds and derivatives thereof, processes for the preparation thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.